Imatinib Grindeks (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This blocks proliferative signaling pathways, leading to reduced tumor cell growth and induction of apoptosis in cells that rely on these kinases for survival.

The dose of Imatinib Grindeks is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and treatment response. Only a qualified healthcare professional should determine the appropriate regimen.

Imatinib is classified as contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential should use effective contraception. Breastfeeding is not recommended while receiving Imatinib, as the drug is excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine‑kinase inhibitor approved for CML and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib have broader kinase inhibition profiles and may be used when resistance or intolerance to imatinib occurs, but Imatinib retains a well‑characterized safety and efficacy record.

Imatinib Grindeks should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Do not store in bathrooms or near heat sources, and keep the container tightly closed when not in use.

Imatinib Grindeks is taken orally, usually once daily, with or without food. Tablets should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their physician and not alter the timing without medical advice.

Serious risks include severe neutropenia or other cytopenias, hepatotoxicity, cardiac dysfunction, pulmonary arterial hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if symptoms like unexplained fever, jaundice, shortness of breath, or severe rash develop.

Patients with known hypersensitivity to imatinib or any of its excipients should avoid the drug. It is also contraindicated in pregnant women and should be used with caution in individuals with significant hepatic, renal or cardiac impairment. The prescribing clinician must evaluate each patient’s medical history before initiating therapy.